BeyondSpring sells majority stake in China unit Bulin to Biolin to fund DUBLIN-4 trial
BeyondSpring will sell its China unit Bulin, which it indirectly owns a majority stake in, to Biolin Investment in non-cash consideration funding DUBLIN-4 development in China covering about 221 patients.
Story updates
11:10:45 AM UTC
SquawkNews
Sept 29 (Reuters) — Beyondspring Inc: Beyondspring Announces Fda Fast Track Designation For Plinabulin In Post-ici Non-squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis Beyondspring - Sells Majority Equity Interest In Chinese Subsidiary To Fund Dublin-4 Trial In China Beyondspring - Retains Global Rights To Plinabulin Outside Greater China Source text:... Further company coverage: BYSI.O (Reuters.Briefs@thomsonreuters.com;;)